mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor (Q46119164)
Jump to navigation
Jump to search
scientific article published on 17 February 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor |
scientific article published on 17 February 2009 |
Statements
1 reference
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor (English)
1 reference
Anne Boulay
1 reference
Heidi A Lane
1 reference
Jeanette M Wood
1 reference
Paul M J McSheehy
1 reference
Peter R Allegrini
1 reference
Joseph Brueggen
1 reference
Amanda Littlewood-Evans
1 reference
Sauveur-Michel Maira
1 reference
Georg Martiny-Baron
1 reference
Christian R Schnell
1 reference
Patrizia Sini
1 reference
Terence O'Reilly
1 reference
17 February 2009
1 reference
15
1 reference
5
1 reference
1612-1622
1 reference